Compare PCVX & ATI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | ATI |
|---|---|---|
| Founded | 2013 | 1960 |
| Country | United States | United States |
| Employees | N/A | 7600 |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 24.2B |
| IPO Year | 2020 | 1996 |
| Metric | PCVX | ATI |
|---|---|---|
| Price | $57.63 | $187.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $88.25 | ★ $153.75 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.76 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $4,043,500,000.00 |
| Revenue This Year | N/A | $9.52 |
| Revenue Next Year | N/A | $9.02 |
| P/E Ratio | ★ N/A | $225.95 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.10 | $70.42 |
| 52 Week High | $65.00 | $205.31 |
| Indicator | PCVX | ATI |
|---|---|---|
| Relative Strength Index (RSI) | 64.93 | 49.24 |
| Support Level | $42.30 | $139.22 |
| Resistance Level | $58.95 | $205.31 |
| Average True Range (ATR) | 2.46 | 6.97 |
| MACD | 1.00 | -2.08 |
| Stochastic Oscillator | 84.47 | 12.16 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.